Updated 21 October 2026.
Britain can recognise European medical-device conformity assessments and still regulate devices used in Britain. The real sovereignty question is not whether those two things can coexist. It is which decisions Britain chooses to make independently, what capability it retains to make them, and whether that arrangement serves patients better than an additional approval process.
The government's indefinite CE-recognition decision therefore deserves a more serious debate than "Brexit reversed" or "red tape removed". It is a choice about where regulatory effort should sit. For clinical AI, that choice is especially consequential because a static market-entry event may reveal only part of a system's behaviour over time.
Separate rule-making from recognition
A country can write domestic rules, operate a domestic route and recognise another jurisdiction's assessment. These functions overlap but are not identical. Recognition can be conditional, and continued access can remain subject to local obligations and enforcement.
The consultation outcome preserves domestic responsibilities while committing to the planned recognition changes. UKCA remains available. That makes the position more nuanced than a complete outsourcing of British device regulation.
Nevertheless, commercial incentives matter. When manufacturers choose a European route because it serves several intended markets, the European requirements can become influential in how products are designed. Britain may retain the legal ability to differ while reducing the practical incentive for businesses to design around those differences. That is the strongest version of the rule-taker concern.
Why duplication is not automatically independence
Two assessments are not necessarily twice as informative. They may examine substantially overlapping evidence, consume scarce specialist capacity and introduce delays without finding materially different problems. Alternatively, a second assessment might identify risks missed by the first. The policy question is which outcome is likely for a given category and whether the marginal benefit justifies the cost.
An assessment regime should be judged against avoidable harm, timely access and the quality of evidence it generates. A nationally branded certificate is not valuable merely because it is national. Equally, international alignment is not valuable merely because it is convenient for manufacturers.
This is why the public-interest case needs more than a competitiveness slogan. A faster route should be accompanied by a clear explanation of how safety concerns are identified, shared and acted upon. Otherwise, reduced duplication can become a description of reduced visibility rather than better regulatory design.
Post-market authority is a meaningful form of control
The MHRA's post-market surveillance framework addresses activity after devices enter use. That is important for all devices, but particularly for software whose clinical effect depends on configuration, data and updates.
Consider an illustrative decision-support product that performs acceptably in its initial evaluation but behaves differently after a retrieval change. A second historical certificate would not necessarily reveal the new problem. A responsive reporting process, reliable version identification and access to deployment evidence might.
That does not make pre-market assessment unnecessary. It means oversight is a sequence rather than a ceremony. A regulator's ability to investigate, require corrective action and understand patterns of failure is a substantive source of sovereignty even where an initial conformity assessment is recognised.
Patients should not disappear from the debate
The full government response records concerns about safety, accountability and trust alongside support for reducing duplication. Those concerns should not be dismissed as resistance to innovation. A patient harmed by a device experiences the effectiveness of the whole regulatory system, not the elegance of its administrative design.
Clinical AI introduces an additional communication challenge. People may struggle to distinguish the doctor's judgement, the software's suggestion and the evidence that informed either. A credible policy should make responsibility easier to understand rather than encourage the impression that certification removes uncertainty.
An adequate public explanation would identify who can investigate a concern, how a harmful output is preserved and whether a product can be restricted or corrected. These are more useful questions than whether the software was developed under a British or European company name.
Where Britain could still lead
The National Commission's recommendations and the government's response point towards work on AI-specific regulation, including functionality and lifecycle issues. They provide a policy agenda, not evidence that a new framework has already delivered better outcomes.
Britain could distinguish itself through practical methods for evaluating changes, monitoring real deployment and producing usable guidance for multifunction products. Another opportunity is clearer evidence expectations for the interaction between clinician and system: not merely whether an answer is technically correct, but whether users notice missing information and can act on uncertainty.
Such leadership would be compatible with recognising European conformity assessments. It would focus resources on problems that are not solved by duplicating the entry paperwork. The test would be whether those methods are trusted, proportionate and useful enough to influence practice beyond Britain.
The industrial-policy tension remains real
A country may become an attractive destination for selling medical AI without becoming the most attractive place to build it. Recognition improves one part of the market-access calculation. It does not itself supply research funding, implementation partners, specialist staff or customers willing to support evaluation.
A credible industrial strategy would therefore connect regulation to evidence generation and adoption. British companies need realistic opportunities to demonstrate value, not merely protection from imported products. NHS organisations need incentives and capacity to test promising tools without absorbing unmanaged risk.
This distinction matters to iatroX and other specialists. A useful domestic platform should earn adoption through relevance, clarity and outcomes appropriate to its function. It should not depend on the assumption that regulatory separation will permanently shelter it from competition.
A better question than "rule-taker or rule-maker"
The binary misses the practical objective: an effective system that can learn, intervene and maintain public trust. Britain could be highly independent on paper but slow to recognise emerging problems. It could also share conformity infrastructure while exercising strong judgement over actual deployment.
For clinicians, the immediate discipline is to keep regulatory status separate from clinical reasoning. A recognised product can still produce an answer requiring scrutiny. iatroX's source-focused methodology is relevant to that scrutiny, but it too should be judged against the quality and applicability of the information presented.
The more useful measure of sovereignty is not how many processes are exclusively British. It is whether British institutions retain the capability and authority to protect patients while enabling worthwhile innovation. Indefinite CE recognition changes the means available; it does not settle whether those means will be used well.
Frequently asked questions
Does CE recognition mean the EU regulates every device used in Britain?
No. Great Britain retains domestic requirements and MHRA oversight. Recognition concerns a route to demonstrating conformity, not the removal of local authority or every other obligation.
Can Britain still develop different AI-specific rules?
The government is pursuing further reform. The content and operation of future requirements need to be assessed as they are implemented, rather than assumed from policy commitments alone.
Is regulatory sovereignty necessarily worth an additional approval process?
That is a policy judgement requiring evidence about safety, access and cost. An additional process is valuable when it adds meaningful assurance, not merely because it duplicates an assessment domestically.
Keep regulatory claims connected to evidence
Explore the iatroX tools guide for task-specific comparisons of clinical AI, reference and learning platforms.